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Abstract 
 
Cancer is not a unique disease but a generic term used to encompass a set of more 
than two hundred diseases. Although possessing biological and molecular 
heterogeneity, cancers share common characteristics such as uncontrolled growth 
and their increased resistance to apoptosis induction.  Mitochondria are the 
powerhouse of the cells but also their suicidal weapon stores. Therefore, it is not 
surprising that mitochondria have emerged as intriguing targets for anticancer 
therapy. Compounds that directly affect mitochondrial functions and trigger apoptosis 
are considered as promising chemotherapeutics used to eliminate tumor cells. 
Triterpenoids are a class of natural occurring compounds whose anticancer activity 
has already documented and linked to apoptosis induction via direct mitochondrial 
alterations. The objective of the present work was to investigate the potential 
mitochondrial toxicity induced by novel dimethylaminopyridines of pentacyclic 
triterpenes derivatives, using isolated hepatic mitochondrial fractions and comparing 
their effectively as anti-cancer agents in three distinct cell lines.  
The present work supports the idea that DMAP triterpenoid derivatives can be 
promising chemotherapeutic agents since effects were more prominent in cancer vs. 
non-cancer cells. Assays on isolated hepatic mitochondria showed a multitude of 
different effects in several targets, although most can induce the mitochondrial 
permeability transition pore (MPTP). In fact, we can speculate that MPTP induction 
may be one mechanism by which these compounds cause cell death. Nevertheless, 
further refinement of the molecules can be expected since mitochondrial toxicity in 
non-target organs is likely. We also confirm that the test compounds act in different 
ways according to their number, orientation and position of DMAP groups. 
 
Keywords: Triterpene derivatives, mitochondria, cancer cells, transition pore 
 
xix 
 
Resumo 
 
O cancro não é uma doença particular mas sim um termo genérico que abrange mais 
de duzentas patologias. Embora exista heterogeneidade a nível molecular e 
biológico, os diferentes tipos de cancro apresentam características comuns como o 
crescimento descontrolado e uma maior resistência à indução de apoptose. As 
mitocôndrias não só são responsáveis pela produção de energia na célula como 
também encerram alguns factores pró-apoptóticos. Assim, não é de surpreender que 
as mitocôndrias se tenham tornado alvo de interesse na terapia anticancerígena. 
Compostos que directamente afectam as funções mitocondriais e que induzam 
apoptose são considerados quimioterapêuticos promissores para eliminar as células 
tumorais. Os triterpenóides são uma classe de compostos que existem na natureza 
cuja acção anticancerígena foi já descrita como estando associada à indução de 
apoptose por efeitos directos na mitocôndria. O objectivo deste trabalho centrou-se 
em investigar a potencial toxicidade mitocondrial induzida por novas 
dimetilaminopiridinas, derivadas de triterpenos pentacíclicos, usando fracções 
mitocondriais isoladas de fígado e comparando o seu efeito anti-tumoral em três 
linhas celulares distintas. 
Este trabalho sustenta a ideia de que os DMAP derivados de triterpenóides podem 
ser promissores agentes quimioterapêuticos pois os seus efeitos são mais 
proeminentes em células cancerígenas que em células normais. Ensaios com 
mitocôndrias isoladas de fígado mostraram que estes compostos têm efeitos 
diferentes e alvos também diferentes embora a maioria consiga induzir o poro 
transitório de permeabilidade mitocondrial. De facto, podemos especular que a 
indução do poro de permeabilidade transitória mitocondrial pode ser um dos 
mecanismos pelo qual estes compostos induzem morte celular. No entanto, um 
aperfeiçoamento das moléculas pode ser esperado uma vez que a toxicidade 
mitocondrial em outros órgãos é provável. Confirmámos também que os compostos 
testados actuam de diferentes maneiras de acordo com o número, orientação e 
posição dos grupos DMAP. 
 
Palavras-chave: Derivados de triterpenóides, mitocôndria, células cancerígenas, poro de 
permeabilidade transitória. 
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Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
1.1 Mitochondria: Structure and Function 
Mitochondria, from the Greek mito (thread) and chondros (grains) are small 
organelles that exist as a network in the cytoplasm of eukaryotic cells, performing a 
variety of important functions including energy production, calcium homeostasis, fatty 
acid metabolism and heme and pyrimidine biosynthesis [1-3]. Moreover, mitochondria 
play a critical role in programmed cell death (apoptosis) [1, 4]. Mitochondrial structure 
comprises two different membranes - the mitochondrial outer membrane (MOM) and 
the mitochondrial inner membrane (MIM), that functionally separate two distinct 
compartments, the intermembrane space (IMS) and the mitochondrial matrix [5] 
(Figure 1, panel B). The outer membrane encloses this organelle and is identical to 
other cell membranes since it contains cholesterol and is permeable to ions. In 
counterpart, the inner membrane is rich in cardiolipin (an acidic and hydrophobic 
phospholipid) and is devoided of cholesterol, being impermeable to ions and small 
molecules, which require specific transport proteins to move across inner membrane 
[6]. The inner membrane  surrounds the matrix which contains a small circular 
genome and includes multiple invaginations towards the matrix called cristae, where 
different respiratory complexes (complexes I–IV) and ATP synthase (complex V) 
responsible for oxidative phosphorylation exist [7]. 
CHAPTER 
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1.1.1 Organization and Genomics 
Also known as mitochondrial reticulum, the mitochondrial network continuously 
moves, fuses and divides in a process tightly regulated by cellular stimuli and 
disturbances inside this organelle [8]. The shape greatly varies from tissue, 
developmental and physiological states. Within a cell, the distribution of mitochondria 
is unequal, depending on the cellular energetic or metabolic requests [9-11]. The 
overall shape of mitochondrial network results from an equilibrium between fusion 
and fission events [12]. This events allow the exchange of organelles contents such 
as membrane lipids, proteins, solutes, metabolites and mitochondrial DNA [8], as well 
is committed to the electrochemical gradient balance [13] and is crucial to preserve 
mitochondrial integrity and functionality. 
 
 
1.1.2 Oxidative Phosphorylation and Energy Production 
The available energy within a living cell is performed by a conversion of dietary fats 
and carbohydrates into reducing equivalents. Mitochondria are the powerhouses of 
the cell and also execute a key role in other important metabolic pathways. Pyruvate 
is formed in the cytosol as an end-product of glucose metabolism (glycolysis) and can 
undergo lactic acid or alcoholic fermentation in the absence of oxygen (anaerobic 
conditions). Under aerobic conditions, pyruvate can be converted to acetyl coenzyme 
A (acetyl-CoA) by pyruvate dehydrogenase (PDH) in the mitochondrial matrix [2] that 
enters in the Krebs cycle, and is oxidized to generate reducing equivalents in the form 
of NADH and ubiquinol (Figure 1, panel A). Intermediates of the Krebs cycle are also 
quite important in other metabolic pathways since they are biosynthetic precursors of 
heme and amino acids [14]. Mitochondria can be either involved in the reduced 
equivalents production through β-oxidation of fatty acids [15]. The end product of this 
pathway is, once again, acetyl-CoA that can also enter in the Krebs cycle. All of these 
equivalents, that are produced by different pathways, are funneled into the electron 
transport chain (ETC) that is located mostly in mitochondrial cristae, and ultimately 
lead to the production of adenosine triphosphate (ATP) by oxidative phosphorylation 
(OXPHOS) [7, 16-17]  (Figure 1, panel C). The electrons are passed along the chain 
(OXPHOS complexes I-IV) and the energy derived from them is used to pumps out 
protons across the inner membrane at complexes I, III and IV, which creates an 
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electrochemical gradient between both sides of inner membrane. This 
electrochemical gradient is a proton-motive force that drives the re-entry of protons 
towards the matrix through complex V (ATP synthase) for ATP synthesis [17]. The 
ATP that is produced becomes available for the entire cell after the mitochondrial 
carrier ANT (mitochondrial adenine nucleotide translocase) switched it by a cytosolic 
ADP. Molecular oxygen is the final electron acceptor, which is reduced to water via a 
sequential four-electron transfer. However, single electrons that pass across the ETC 
can escape and perform a single electron reduction of molecular oxygen. This 
phenomenon occurs continuously even in normal conditions leading to formation of 
superoxide anion (O2
●-). 
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Figure 1: Mitochondria play a critical role in ATP production, biosynthesis, calcium homeostasis and cell 
death. The figure represents some of these functions: (Panel A) The Krebs cycle occurs in the matrix 
and supplies reducing equivalents for oxidative phosphorylation, besides participating as intermediate in 
several biosynthetic pathways. (Panel B) Overall view of mitochondria morphology: The MOM encloses 
the organelle within the cell; the MIM separates functionally the matrix from the mitochondrial inter-
membrane space (IMS). (Panel C) Oxidative phosphorylation: electrons from the Krebs cycle are 
transferred along the respiratory chain. The energy derived from electron transfer is used to pump out 
protons across the inner membrane at complexes I, III and IV, creating a proton electrochemical gradient 
between both sides of inner membrane. This electrochemical gradient forms a proton-motive force that is 
used to drive the re-entry of protons to the matrix through complex V (ATP synthase) for ATP production 
[17]. A small amount of electrons can leaks towards the matrix through complex I and complex III 
performing a one-electron reduction of molecular oxygen forming superoxide anion (O2
●-
). Figure 
adapted from [2], with permission. 
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1.1.3 Reactive Species and Oxidative Stress 
“Living with the risk of oxidative stress is a price that aerobic organisms must pay for 
more efficient bioenergetics” (Skulachev, 1996 cit in [18]). Among the reactive 
species that are produced within a living cell, reactive oxygen species (ROS) are the 
most significant. Indeed, ROS are produced continuously as a by-product of 
OXPHOS but mitochondria has an efficient antioxidant network that can counteract 
detrimental effects of these reactive species and perform the redox balance. 
Oxidative damage, so-called oxidative stress arises when an imbalance in the redox 
steady-state occurs and the ROS production exceeds the capacity of the cell to 
detoxify them. Oxidative stress is largely related with aging [19] and is often 
associated with various disorders, such as cancer [3]. 
 
 
1.2 The Role of Mitochondria in Cancer 
Cancer is not only a definite disease but a generic term used to encompass a set of 
more than two hundred diseases. Besides biological and molecular heterogeneity of 
cancers, all share common characteristics. Generally, cancer cells uncontrolled 
growth and invasive potential are the primary features that describe them but there 
are more features to be addressed. Six cell-intrinsic hallmarks have been originally 
proposed by Hanahan and Weinberg in 2000 to define a cancer cell: self-sufficiency 
in growth signals, insensitivity to antiproliferative signals, acute replicative potential, 
tissue invasion with metastasis, sustained angiogenesis, and apoptotic resistance 
[20]. Subsequently, avoidance of the immune response [21], enhanced anabolic 
metabolism [22] and autophagy inhibition [23] have been proposed as additional 
features that characterize cancer cells.  Eradication of cancer cells by non-surgical 
resources, ultimately leads to apoptosis [24]. Mitochondria occupy a strategic position 
between bioenergetic/biosynthetic metabolism and cell death regulation. Since cancer 
cells are more resistant to cell death induction than their normal counterparts, 
mitochondria are emerging as idealized targets for anticancer therapy [25]. Indeed, 
agents that target mitochondria are considered as promising cancer therapeutics 
even in cancer cells that are resistant to conventional therapies [26-27]. 
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1.2.1 Cell Death 
Unlike what was thought until a few years ago, cell death is not a process observed 
only when cell tissues were injured by external factors. Actually, cell death is an 
evolutionary conserved and genetically regulated process that is crucial for 
development, morphogenesis and homeostasis in tissues [28]. Programmed cell 
death (PCD) was the first designation attributed to this regulated process. Later, Kerr 
et al. introduce the term apoptosis [29] to designate programmed cell death. 
Apoptosis plays an essential role in the maintenance of homeostasis by eliminating 
damaged, infected or superfluous cell in a regulated form that minimizes inflammatory 
reactions and damages in neighboring cells [1, 30]. An imbalance in this process may 
contribute to the development of many disorders and even the development of cancer 
[31-32]. Apoptotic cells exhibit specific morphological alterations, including chromatin 
condensation, nuclear fragmentation, and plasma membrane blebbing. The late 
stages of apoptosis are characterized by fragmentation of the cell membrane into 
vesicles (apoptotic bodies) which contain intact cytoplasmatic organelles or fragments 
of the nucleus. These vesicles are recognized by macrophages, preventing 
inflammatory responses [28, 33]. 
There are two main pathways by which a cell can engage apoptosis: extrinsic (or 
receptor-mediated) apoptotic pathway and intrinsic (or mitochondria-mediated) 
apoptotic pathway [33] (Figure 2). The apoptotic process is performed by a family of 
cysteine proteases that are produced as pro-enzymes and must be proteolytically 
cleaved to produce active forms. These proteases, known as caspases, specifically 
cleave their substrates at aspartic residues and are categorized into initiators (such 
as caspases -8 and -9) and effectors or executioners (such as  caspases -3 and -7) 
[1, 31]. The extrinsic pathway is most commonly activated within the immune system 
and requires the binding of ligand-induced activation of death receptors at the cell 
surface (such as TNF and TRAIL) [34]. The connection between these specific 
ligands with their receptors is followed by formation of the death-inducing signaling 
complex (DISC) that performs the activation of pro-caspase 8 and subsequent 
activation of downstream executioners caspases [4]. Mitochondria are central players 
in the intrinsic apoptotic pathway. In addition to its role as a powerhouse of the cell, 
mitochondria harbors a pool of pro-apoptotic factors which reside in mitochondrial 
inter membrane space. During the intrinsic pathway, pores are formed in the 
mitochondrial outer membrane in a process called mitochondrial outer membrane 
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permeabilization (MOMP). The pro-apoptotic factors such as cytochrome c and 
apoptotic-inducing factor (AIF) that are usually confined to the mitochondrial inner 
membrane space are released into cytosol [35]. In addition, the opening of the so-
called mitochondrial permeability transition pore in the inner mitochondria membrane 
can also occur during apoptosis, leading to the collapse of ∆ψm and resulting in 
mitochondrial swelling and rupture of the outer membrane [36]. Although the effects 
of pro-apoptotic factors that are released in the cytosol is well characterized, the 
mechanisms underlying the MOMP remains controversial [37]. Induction of the 
mitochondrial permeability transition can also be considered a more drastic 
phenomenon which, if widespread to the entire mitochondrial population, can result 
into severe cell ATP depletion and cell death by necrosis [38]. 
Several mechanisms have been proposed to explain MOMP, although they generally 
fall under two classes of mechanisms [32-33]. Each may function under different 
circumstances. The first model of MOMP involves members of Bcl-2 proteins family 
and only the MOM permeabilization is implicated (Figure 2). Bcl-2 family comprises 
three subgroups: the anti-apoptotic Bcl-2 family members such as Bcl-2 ad Bcl-xL, 
the pro-apoptotic Bax/Bak sub-family and the pro-apoptotic BH3-only proteins such 
as Bid and Puma. BH3-only proteins link cell death signals to mitochondria and here, 
the interplay between various members of the Bcl-2 family determines the fate of the 
cell [39]. A mild change in the dynamic balance of these proteins may result either in 
inhibition or exacerbation of cell death. As described above, the second model of 
mitochondrial outer membrane permeabilization, involving the mitochondrial 
permeability transition (MPT), occurs in response to apoptosis-induced stress and is 
originally thought to span both inner and outer mitochondrial membranes (Figure 3).  
In this model, a non-specific channel opens and itself is permeable to solutes up to 
1.5 kDa and water [40-41]. The overture of this channel leads to dissipation of 
mitochondrial transmembrane electric potential (∆ψm) and to the concomitant 
mitochondrial swelling, which stretches both membranes and burst MOM. The 
mitochondrial pro-apoptotic factors are released into cytosol and initiates intrinsic 
apoptotic pathway. 
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Figure 2: An overview of extrinsic and intrinsic pathways of apoptosis. Extrinsic pathway requires the 
binding of specific ligands such as TNF and TRAIL to their death receptors at the cell surface which 
triggers the formation of DISC complex that performs the activation of pro-caspase 8 and subsequent 
activation of downstream executioners caspases. During intrinsic pathway, pores are formed in the MOM 
in a process called mitochondrial outer membrane permeabilization (MOMP). One mechanism that might 
explain this process involves members of Bcl-2 proteins family the anti-apoptotic proteins such as Bcl-2 
and Bcl-xL and pro-apoptotic Bax/Bak proteins [35]. A small amount can exist in the MOM but the bulk of 
these proteins exist in the IMS. In response to internal stimulus, pro-apoptotic proteins are inserted in 
MOM and oligomerize leading to a formation of channels that allows the release of pro-apoptotic factors. 
Once in cytosol, cytochrome c interacts with Apaf-1 performing the recruitment of pro-caspase 9 and 
altogether forms the apoptosome complex that activates caspase 9 and leads to activation of effectors 
caspases 3 and 7. Endo G and AIF go to the nucleus and perform de DNA framentation. The intrinsic 
and extrinsic pathways can crossroad in mitochondria leading to signal amplification. Figure adapted 
from [2], with permission. 
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Figure 3: Molecular models for the mitochondrial permeability transition (MPT) pore. On the top: the 
original model for the MPT pore which considers the assembling of the VDAC (so-called porin) protein in 
the outer mitochondrial membrane, ANT in the inner mitochondrial membrane and CypD in the matrix 
[42]. On the bottom: the revised model according to recent findings; VDAC is no longer a component of 
the PTP (permeability transition pore) and seems that MOM is also not involved in the initiation of this 
process. Like VDAC, ANT is no longer a component of the pore in this model, but apparently regulates 
its activity. CypD is the only one that remains as a critical component of this complex. Another protein 
has been added to the model as a pore-forming unit, the mitochondrial phosphate carrier (PiC) [42]. 
Although the precise molecular composition of PTP complex is still debated, it is clear that under some 
circumstances (like an overload of calcium, excess of ROS production) the mitochondrial inner 
membrane permeability is disrupted. MIM becomes permeable to ions and water causing mitochondrial 
swelling. Since mitochondrial outer membrane lacks invaginations, mitochondrial swelling breaks MOM 
and pro-apoptotic factors that were trapped in MIM space are released into cytosol and initiate intrinsic 
apoptotic pathway [39]. 
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1.2.2 Mitochondrial Alterations in Carcinogesis 
Mitochondrial alterations are one of the more recurrent features in cancer cells [43]. 
The first suggestion about the role of mitochondria in tumor metabolism appeared in 
1920’s, when Otto Warburg observed higher glucose consumption in tumor cells, 
even under normoxic conditions [44]. Following this observation, Warburg 
hypothesized that tumor cells produce most of their ATP by aerobic glycolysis 
(Warburg effect). Later, other mitochondrial alterations have been reported in cancer 
cells. Alterations in oxidative phosphorylation resulting from mitochondrial 
dysfunction, such as mutations in mitochondrial and nuclear genes that encode 
proteins involved in OXPHOS, have been hypothesized to be involved in 
tumorigenesis [45]. OXPHOS impairment can enhance ROS production which in turn 
accelerates the rate of DNA mutation. This scenario has been proposed to be 
involved in the pathophysiology of cancer. Also, mitochondrial DNA copy number 
decrease has been associated with resistance to apoptosis and increased 
invasiveness [46]. The loss-of-function of mitochondrial-specific enzymes like 
fumarate and succinate dehydrogenase, results in the accumulation of specific 
metabolites in the cytosol, that can favor the activation of transcription factors such as 
HIF (hypoxia inducible factor) which in turn can direct metabolism to aerobic 
glycolysis [47]. Such  alterations  in  cellular  metabolism  may  favor  tumor  cell  
growth  by increasing  the  availability  of  biosynthetic  intermediates  needed for 
tumor cells proliferation and adaptation to tumor microenvironments [48]. 
Another commonly observed difference in mitochondria cancer cells when compared 
to their normal counterparts is the increased mitochondrial transmembrane electric 
potential (∆ψm) in the former [49-50]. Mitochondrial transmembrane electric potential 
is increased to greater negative values (usually -120 to -170 mV, negative inside) 
which represents a range of ~60mV [51]. Many proposals can explain these 
differences and include, among others, alterations in mitochondrial respiratory 
enzyme complexes, electron carriers and in membrane lipid metabolism [52]. Cancer 
cells exhibit in general an increase in glycolysis and a decrease in oxidative 
phosphorylation (OXPHOS) activity (Warburg effect) that per se can explain the 
greater mitochondrial transmembrane potential. Reduced OXPHOS activity leads to a 
build-up of protons in mitochondrial intermembrane space, increasing ∆ψm [49]. 
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1.2.3 Mitochondria as a Pharmacological Target in Cancer 
Therapy 
Despite the diversity of the physical-chemical properties or the intended mechanisms 
of action, anticancer drugs exert typically cytotoxic effects by initiating intrinsic death 
pathways that ultimately converge in mitochondria [24]. The main goal of these 
anticancer drugs is to achieve optimal cytotoxic efficiency and tissue selectivity [53]. 
In other words, anti-cancer drugs are developed with the expectation that they kill 
more effectively cancer cells with minimal adverse effects to normal tissues. When 
classical chemotherapeutic agents cause a primary insult, such as DNA damage, p53 
content increase and pro-apoptotic proteins translocate to mitochondria, causing the 
release of cytochrome c and subsequent caspase activation. Frequently, many 
cancers regress after initial chemotherapy treatments. However, if some of these 
cancer cells acquired the ability to survive, quite often the cancer returns. 
Chemoresistant cells have acquired the ability to overcome death signals in different 
ways, including loss or mutation of p53 and overexpression of anti-apoptotic 
molecules like Bcl-2 [24]. Therefore, compounds that directly induce mitochondrial 
intrinsic pathway can theoretically bypass primary or acquired resistance mechanisms 
that frequently exist or develop towards classical chemotherapeutics [26] (Figure 4). 
Indeed, mitochondria are emerging nowadays as idealized targets for anticancer 
therapy [26]. 
On the other hand, mitochondria form cancer cell exhibit unique features that per se 
offer interesting ground for the development of novel selective anticancer 
therapeutics. As seen above, mitochondrial transmembrane electric potential is 
increased at least ~60mV in some cancer cell types. It was already recognized that 
delocalized lipophilic compounds (DLC) accumulate in mitochondria matrix driven by 
electrochemical gradient [51]. Some of these DLC are sensitive to higher ∆ψm and 
selectively accumulate in cancer cells mitochondria. According to the Nernst 
equation, a range of 60 mV in ∆ψm is sufficient to account for a 10-fold greater 
accumulation of the cationic compound in malignant cells [49, 54]. Moreover, the 
greater plasma membrane potential (negative inside) observed in some carcinoma 
cells when compared to their normal counterpart accounts for further increased DLC 
accumulation in carcinoma mitochondria [27, 51]. 
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As discussed above, anticancer drugs are developed with the expectation that they 
are more effectively targeted to malignant cells than to normal cells.  Taking 
advantage of the singular mitochondrial features, the development of drugs that 
directly exert their function in mitochondria are promising approaches in cancer 
eradication. 
 
 
Figure 4: Mitochondria as a main target in cancer therapy [26]. In contrast to many conventional 
anticancer drugs, which rely on upstream signaling cascades to engage the mitochondrial apoptosis 
pathway, mitochondria-targeting drugs offer the advantage to act independent of these upstream events 
that are often blocked in cancers. Adapted from [24]. 
 
 
1.3 Triterpenoids as Anticancer Drugs 
Triterpenoids are naturally occurring compounds with ubiquitous distribution. It is 
believed that their broad occurrence in terrestrial and marine flora is due to their 
physiological function in defense against plant-pathogens [55]. This has lead to the 
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expectation that triterpenoids could also act against pathogens that cause human and 
animal diseases [56]. Indeed, the biological activity of some triterpenoids in 
mammalian cells, including antiviral [57], antifungal, anti-inflammatory [58] and even 
antitumor effects has already been documented [59-60]. Betulinic acid is one of these 
natural compounds that displays notable level of discrimination in promoting 
apoptosis of melanoma cancer cells [61]. Subsequent studies demonstrate that 
betulinic acid also exhibits activity in glioma, ovarian carcinoma and cervical 
carcinoma cell lines [60]. 
Interestingly, the anticancer activity of some triterpenoids has been linked to their 
ability to induce apoptosis via direct mitochondrial alterations [62]. Indeed, 
triterpenoids compounds are emerging as promising in the cancer research. These 
natural products can largely be extracted from the birch bark, however, the use of 
these triterpenoids remains quite limited, due to their low solubility, high pH and high 
molecular weight [56]. Taking advantage of biological activity structures, derivatives of 
triterpenoids are synthesized to overcome these limitations. Derivatives are positively 
charged with the main goal to target mitochondrial cancer matrix. 
 
 
1.4 Aim 
Our research group has previously tested a number of dimethylaminopyridine 
(DMAP) derivatives of lupane triterpenoids on human melanoma cell lines [56]. These 
compounds induced mitochondrial fragmentation and depolarization, along with an 
inhibition of cell proliferation. The potency of their effects was correlated with the 
number, position, and orientation of the DMAP groups. Overall, the extent of 
proliferation inhibition was shown to mirror the effectiveness of mitochondrial 
disruption. The present thesis is the follow-up of this previous study, investigating the 
direct toxicity of some of the DMAP compounds on isolated hepatic mitochondrial 
fractions in order to identify mitochondrial mechanisms that can explain their cellular 
effects. We also investigated the same compounds in two human breast cancer cell 
lines vs. a non-tumor cell line to confirm that the same compounds would have 
specificity towards the breast tumor cell lines.  
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Materials and Methods 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.1 General Chemicals 
Mitotracker Red CMXRos (#M-7512) and ProLong Gold antifade reagent with DAPI 
(#P-36931) were obtained from Molecular Probes (Invitrogen, Eugene, OR); 
Sulforhodamine B (SRB) was obtained from Sigma (St Louis, MO). All other reagents 
and chemical compounds used were of the greatest degree of purity commercially 
available. In the preparation of every solution, ultrapure distilled water, filtered by the 
Milli Q from a Millipore system, was always used in order to minimize as much as 
possible contamination with metal ions. 
 
 
2.2 Synthesis and Preparation of the Compounds 
Triterpenoid derivatives were produced in the Laboratory of Chemical Extractive 
Natural Resources Research Institute, University of Minnesota, Duluth, USA by Drs. 
Pavel Krasutsky and Dmytro Krasutsky. Birch bark lupane triterpenoids betulin and 
betulinic acid (Figure 5) have been chosen as basic natural precursors for synthesis 
of dimethylaminopyridine (DMAP) derivatives of pentacyclic triterpenes (Figure 6). 
Betulin with 99% + purity was isolated  from the extract of outer birch bark of Betula 
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papyrifera – the North American commercial birch tree [60] – and betulinic acid was 
then synthesized from betulin. The compounds were prepared as stock solutions in 
dimethylsulfoxide (DMSO) and the maximum concentrations added were 2 µg/ml in 
cells experiments and 6 µg/mg of protein in mitochondrial experiments. The total 
volume of DMSO was always lower than 0.1% in cell studies and lower than 0.3% in 
mitochondrial toxicity studies, which had negligible effects in all experiments (data not 
shown). 
 
 
  
 
 
 
 
 
Figure 5: Synthesis of betulinic acid from betulin in a two step process. (A)  Birch back lupane 
triterpenoid betulin isolated from Betula papyrifera. (B) Betulinic aldehyde wich is an intermediate product 
of betulinic acid synthesis. (C) Betulinic acid synthesized from betulin.  Adapted from [60], with 
permission. 
 
 
 
2.3 Composition of Solutions 
Phosphate buffered saline solution (PBS): 132.0 mM NaCl, 4.0 mM KCl; 1.2 mM 
NaH2PO4. (PBST): PBS with 0.1% Tween 20; 1.4 mM MgCl2; 6.0 mM
 glucose; 0.1 
mM  4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid, N-(2-Hydroxyethyl) 
piperazine-N′-(2-ethanesulfonic acid)  (HEPES). The trypan blue was used as a 
0.04% (w/v) solution in PBS. 
 
 
B C A 
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Figure 6: DMAP compounds synthesized from betulin an betulinic acid. (A) DK 43: Lup-20-(29)-ene-3β-
(4’-Dimethylaminopyridiniumacetoxy) chloride; B) OK 221: Betulin 3β,28-di[(4’-Dimethylaminopyridinium-
1’-yl)acetoxy] bromide; (C) OK 236: Betulinic acid 28-(4’-Dimethylaminopyridinium-1’-yl) bromide; (D) OK 
208: Betulin 30-[4’-(Dymethylamino)pyridinium-1’-yl]-3β,28-di[4’-(Dimethylamino)pyridinium-1-yl acetoxy)] 
tribromide; (E) OK 198: 28-(4’-Dimethylaminopyridinium-1’-acetoxy)-3β-hydroxylup-20(29)-ene chloride. 
Structures were kindly provided by Dr. Pavel Krasutsky from the University of Minnesota, Duluth, USA. 
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2.4 Animal Handling 
Male Wistar-Han rats (8-10 weeks of age) were housed in our accredited animal 
colony (Laboratory Research Center, Faculty of Medicine, University of Coimbra) in 
type III-H cages (Tecniplast, Italy) and maintained in specific environmental 
requirements: 22° C, 45–65% humidity, 15–20 changes/hour ventilation, 12h artificial 
light/dark cycle, noise level < 55 dB. Rats had free access to standard rodent food 
(4RF21 GLP certificate, Mucedola, Italy) and water (acidified at pH 2.6 with HCl to 
avoid bacterial contamination). This research procedure was carried out in 
accordance with European Requirements for Vertebrate Animal Research and 
according to the ethical standards for animal manipulation at the Center for 
Neuroscience and Cell Biology. 
 
 
2.5 Cell Culture 
MCF-7 (HTB-22, ECACC, United Kingdom) and Hs 578T (HTB-125, ATCC, 
Manassas, VA, USA), breast cancer cell lines, as well as BJ normal fibroblasts (CRL-
2522, ATCC, Manassas, VA, USA), were cultured in monolayers in Dulbecco’s 
modified Eagle’s medium (DMEM),  supplemented with 1.8 g/l sodium bicarbonate, 
10% fetal bovine serum, and 1% of penicillin-streptomycin in 75 cm2 tissue culture 
flasks at 37° C in a humidified atmosphere of 5% CO2. Cells were fed every 2–3 days, 
and sub-cultured once they reached 70–80% of confluence.  BJ fibroblasts were only 
used between passage 10 and 25. 
 
 
2.6 Cell Proliferation Measurement 
Sulforhodamine B assay was conducted in order to evaluate the cytotoxic effects of 
Triterpenoids derivatives in tumor and nontumor cell lines, as described by [63]. The 
human fibroblast cell line BJ and the human breast cancer cell line Hs 578T were 
seeded at a density of 1x104 cell/ml in 48-well plates (final volume of 500 µl/well). The 
human breast cancer cell line MCF-7 was seeded at a density of 5x103 cells/ml under 
the same conditions. The test compounds at various concentrations (0.125 µg/ml; 
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0.25 µg/ml; 0.5 µg/ml; 1 µg/ml; 2 µg/ml) were added to each well one day after 
seeding and were incubated for 24h, 48h and 96h. Following treatment, the 
incubation media were removed and cells were fixed in 1% acetic acid in ice-cold 
methanol for at least 30 min. The cells were then incubated with 0.5% (wt/vol) SRB 
dissolved in 1% acetic acid for 1h at 37° C. Unbound dye was removed with 1% 
acetic acid. Dye bound to cell proteins was extracted with 10 mM Tris base solution, 
pH 10, and the optical density of the solution was measured in VICTOR X3 Multilabel 
Plate Reader (Perkin Elmer, Inc.) at 540 nm. The amount of released dye is 
proportional to the number of cells present in the sample and is a reliable indicator of 
cell proliferation [64]. The results were expressed as a percentage of control (non-
treated) cells, taken as 100%, to equalize for different growth rates between cell lines. 
 
 
2.7 Epifluorescence Microscopy 
For detection of morphological alterations in chromatin condensation and 
mitochondrial network distribution cells were seeded in six-well plates containing 
glass coverslips (final volume of 2 ml/well at the same density described in cell 
proliferation measurement) and allowed to attach for 24h. The human breast cancer 
cell lines and the untransformed normal fibroblast line were then treated with desired 
concentrations of test compounds for 48h and 96h. Thirty minutes prior the end of the 
time exposure, the cultures were incubated with Mitotraker Red (7.3 nM) at 37° C in 
the dark, washed with cold PBS and fixed with ice cold absolute methanol overnight 
at -20º C. The cells were then gently rinsed three times with PBST 5 minutes in the 
dark, at room temperature. Glass coverslips were removed from the wells and placed 
on glass slides with a drop of mounting media with DAPI. The images were obtained 
using a 63x objective in a Zeiss Axioskop 2 Plus microscope. 
 
 
2.8 Isolation of Rat Hepatic Mitochondria 
Mitochondria were isolated from the livers of male Wistar rats by conventional 
differential centrifugation [65]. Rats were killed by decapitation and the livers were 
harvested, minced and washed in ice-cold buffer medium containing 250 mM 
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sucrose, 10 mM HEPES (pH 7.2), 1 mM EGTA, and 0.1% lipid-free BSA. Tissue 
fragments were quickly homogenized with a motor-driven Teflon Potter homogenizer 
in the presence of ice-cold isolation medium (7 g/50 ml). Hepatic homogenate was 
centrifuged at 800g for 10 min (Sorvall RC6 centrifuge) at 4° C and mitochondria were 
recovered from the supernatant by centrifugation at 10,000g for 10 min. The 
mitochondrial pellet was resuspended using a paintbrush and centrifuged twice at 
10,000g for 10 min before obtaining a final mitochondrial suspension. EGTA and BSA 
were omitted from the final washing medium, which was adjusted to pH 7.2. Protein 
content was determined by the biuret method [66], using bovine serum albumin (BSA) 
as a standard. 
 
 
2.8.1 Measurement of Mitochondrial Oxygen Consumption 
Oxygen consumption of isolated hepatic mitochondria was polarographically 
monitored with a Clark-type oxygen electrode connected to a suitable recorder in a 1 
ml temperature-controlled, water-jacketed, and closed chamber with constant 
magnetic stirring [67]. The reactions were carried out at 30 °C in 1 ml of standard 
respiratory medium with 1 mg of hepatic mitochondria. Mitochondrial respiratory 
medium comprised 130 mM sucrose, 50 mM KCl, 2.5 mM MgCl2, 5 mM KH2PO4 , 0.1 
mM EGTA and 5 mM HEPES (adjusted at pH 7.2).  The triterpenoid derivative 
compounds were preincubated with 1 mg mitochondria for 1 minute before adding the 
respiratory substrate. This incubation period was carried out to ensure the complete 
internalization of the compound on the membrane due to its lipophilic characteristic. 
The respiratory substrates, glutamate/malate (10 mM/ 5mM) or succinate (5 mM) plus 
rotenone (3 μM), were added to the medium to energize mitochondria, while ADP 
(187.5 nmol/mg protein) was used to induce state 3. In order to block proton influx 
through the ATP synthase under state 4 respiration, 1µg oligomycin was added to the 
system. To uncouple respiration and measure the maximal electron transfer rate 
through the respiratory chain, 1 μM Carbonyl cyanide p-
trifluoromethoxyphenylhydrazone (FCCP) was added. The respiratory control ratio 
(RCR) is a measure of oxidative phosphorylation coupling and is calculated as the 
rate between state 3 and state 4. The ADP/O ratio is indicative of the efficiency of 
oxidative phosphorylation [68]. Both indexes were determined according to Chance 
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and Williams, 1956 [69]. Respiration rates were calculated considering an air 
saturated water oxygen concentration of 236 µM, at 30º C. 
 
 
2.8.2 Measurement of Mitochondrial Transmembrane Electric 
Potential (∆ψm) 
The mitochondrial transmembrane electric potential (ΔΨm) of isolated hepatic 
mitochondria was monitored indirectly in a 1 ml thermostated, water-jacketed, open 
chamber with constant magnetic stirring, using an ion-selective electrode to measure 
the distribution of tetraphenylphosphonium (TPP+) according to previously established 
methods [70]. The reference electrode was Ag/AgCl2. Mitochondrial protein (1 mg) 
was suspended in reaction medium composed of 130 mM sucrose, 50 mM KCl, 2.5 
mM MgCl2, 5 mM KH2PO4 , 0.1 mM EGTA and 5 mM HEPES (pH 7.2, 30° C), and 
supplemented with 3 μM TPP+. Triterpenoid derivative compounds were added to 
mitochondria for 1 minute to allow complete internalization of the compound, followed 
by 5 mM glutamate/2.5 mM malate or 5 mM succinate plus 3 μM rotenone. In order to 
initiate state 3, ADP (125 nmol/mg protein) was added. Valinomycin (0.2 µg) leads to 
a complete collapse of ΔΨm and was added at the end of all experiments to confirm if 
test compounds interfere with the electrode. Assuming a Nernst distribution of the ion 
across the membrane electrode, the equation proposed by Kamo et al.[71] yielded 
the values for transmembrane electric potential. 
 
 
2.8.3 Effects of the Compounds on the MPT: Evaluation of the 
ΔΨm Fluctuations 
The phenomenon of the mitochondrial permeability transition (MPT) takes place when 
a large amount of Ca2+ is accumulated by mitochondria in the presence of an inducing 
agent (Pi). The induction of the MPT pore leads to mitochondrial depolarization. The 
ΔΨm fluctuations associated with the uptake of calcium and the induction of the MPT 
pore were followed with a TPP+-selective electrode (as described above), in an open 
thermostated water-jacketed reaction chamber with magnetic stirring, at 30º C. 
Mitochondria (1mg) were suspended in 1 ml of swelling medium consisting of 200 mM 
sucrose, 10 mM Tris-MOPS (pH 7.2), 10 μM EGTA, 1mM KH2PO4, 3 μM rotenone, 
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supplemented with 3 μM TPP+. The mitochondria were energized with 5 mM 
succinate. Hepatic mitochondria were incubated with the test compounds during 1 
minute before the respiratory substrate to guarantee their total internalization. Two 
aliquots of calcium (CaCl2) were added to the reaction medium in the assays ranged 
from 40 nmol to 60 nmol, depending on mitochondrial preparations. As a control, 
cyclosporin A (1 μM), a specific MPT pore inhibitor [72], was preincubated with the 
mitochondrial preparation in the presence of the highest concentration of the tested 
compounds observed to induce mitochondrial swelling. Another control, with FCCP 
(25x10-3 nmol) was performed in order to induce a small reduction in mitochondrial 
transmembrane potential. Once again, FCCP was incubated with mitochondrial 
suspension before calcium addition.  
 
2.8.4 Effects of the Compounds on the MPT: Measurement of 
Mitochondrial Swelling 
The induction of the mitochondrial permeability transition (MPT) pore leads to 
mitochondrial swelling, which can be estimated by changes in light scattering of the 
hepatic mitochondrial suspension [73]. The turbidity of the mitochondrial suspension 
was measured at 540 nm in a Lambda 45 UV/VIS Spectrometer (Perkin Elmer, Inc.). 
Mitochondrial protein 0.5 mg/ml (final volume of 2 ml) was incubated 1 minute at 30º 
C in swelling  medium containing 200 mM sucrose, 10 mM Tris-MOPS (pH 7.2), 10 
μM EGTA, 1 mM KH2PO4, 3 μM rotenone, and 5 mM succinate in the presence of the 
triterpenoids derivative compounds under study. Mitochondrial swelling was induced 
by adding CaCl2 (ranged from 40nmol to 60nmol depending on mitochondrial 
preparation) to the system. As a control, 1 μM Cs A, a specific MPT pore inhibitor 
[72], was incubated with the mitochondrial preparation in the presence of the highest 
concentration of the test compound observed to induce mitochondrial swelling. 
 
2.9 Statistical Analysis 
Data was loaded to the GraphPad Prism 5.0 program (GraphPad Softwere, Inc.) and 
all results are expressed as means ± standard error of the mean (SEM) and 
evaluated by one-way ANOVA followed by Bonferroni multiple comparison tests. 
Values with p<0.05 were considered as statistically significant. 
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3.1 Effect of DMAP Triterpenoid Derivatives on BJ, Hs 578T 
and MCF-7 Cell Lines Proliferation  
To evaluate whether DMAP triterpenoid derivatives inhibit cell proliferation, two  
human breast cancer cell lines (Hs 578T and MCF-7) and one non-neoplasic human 
fibroblast cell line (BJ) were incubated in the absence and presence of increasing 
concentrations of these compounds ( 0.125, 0.25, 0.5, 1 and 2 µg/ml) for 24, 48 and 
96 hours. As shown in figure 7, OK 198 does not affect cell proliferation of control cell 
line (BJ) for any concentration or time point in study. In contrast, this triterpenoid 
derivative inhibits the proliferation of MCF-7 cell line at all concentrations and time 
points tested. For the Hs 578T cell line, a decrease in cell growth is observed only for 
some conditions: at 24h (1 µg/ml), 48h (concentrations ranging from 0.5 µg/ml to 2 
µg/ml) and for all concentrations at 96h which means that, for this cell line, their effect 
is more dependent on time exposure than on the compound concentration because 
for 96h all concentrations inhibit cell proliferation. Similarly to what happened with OK 
198 in BJ fibroblasts, OK 208 (Figure 8) also did not have any effect on cell 
proliferation but it shows an inhibition of cell proliferation on Hs 578T and MCF-7 cell 
line for the highest  concentrations and longer time exposure. In this case, OK 208 
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have an effect in MCF-7 cell line that is more dose-dependent than time-dependent. 
Cell proliferation in BJ cells is not dissimilar from the control in DK 43 presence 
(Figure 9) except for the highest concentration at 48 and 96 hours. In the Hs 578T cell 
line there is an inhibition immediately visible from the second lowest concentration 
(0.125 µg/ml) at 48 hours and this inhibition is observed for all the concentrations in 
study at the 96 hours time point. Therefore, its effect is more time dependent than 
dose-dependent. The other breast cancer cell line (MCF-7) shows a decrease in cell 
growth at 24 hours for the maximum concentration (2 µg/ml) and has no effects in the 
lowest concentration (0.125 µg/ml) at 48 hours. Surprisingly, for 96 hours, it appears 
that MCF-7 cells can recover from the inhibition of cell proliferation registered at 48 
hours for 0.25 and 0.5 µg/ml concentrations. OK 236 (Figure 10) is the only 
triterpenoid derivative in test that does not present any alteration in cell growth for any 
time exposure or compound concentration. In turn, OK 221 (Figure 11) seem to have 
the most inhibitory power in cell proliferation when compared with other tested 
compounds. Its effect is denoted for all concentrations range and time exposure for 
breast cancer cell lines (Hs 578T and MCF-7) and also for the maximum 
concentration (2 µg/ml) at 24h and for all concentrations at 48 and 96h in BJ normal 
fibroblasts. Thus, the effect of OK 221 is notably dose-dependent. It must be noted 
that the present technique cannot conclude if the effect of DMAP triterpenoid 
derivatives is due to an increase in cell death induction or due to cell cycle arrest. 
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Figure 7: Effect of OK 198 triterpenoid derivative on cell proliferation of one normal human fibroblast cell 
line (BJ) and two human breast cancer cell lines (Hs 578 T and MCF-7). Cells were seeded (see 
Materials and Methods section for further details) and incubated with OK 198 24 hours later, at various 
concentrations during 24, 48 and 96 hours. Cell proliferation assay was accessed at each time by the 
SRB colorimetric assay. Data are means ± SEM of five independent experiments and are expressed as 
% control values. * p < 0.05 vs. control for the same time point. 
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Figure 8: Effect of OK 208 triterpenoid derivative on cell proliferation of one normal human fibroblast cell 
line (BJ) and two human breast cancer cell lines (Hs 578 T and MCF-7). Cells were seeded (see 
Materials and Methods section for further details) and incubated with OK 208 24 hours later, at various 
concentrations during 24, 48 and 96 hours. Cell proliferation assay was accessed at each time by the 
SRB colorimetric assay. Data are means ± SEM of five independent experiments and are expressed as 
% control values. * p < 0.05 vs. control for the same time point. 
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Figure 9: Effect of DK 43 triterpenoid derivative on cell proliferation of one normal human fibroblast cell 
line (BJ) and two human breast cancer cell lines (Hs 578 T and MCF-7). Cells were seeded (see 
Materials and Methods section for further details) and incubated with DK 43 24 hours later, at various 
concentrations during 24, 48 and 96 hours. Cell proliferation assay was accessed at each time by the 
SRB colorimetric assay. Data are means ± SEM of five independent experiments and are expressed as 
% control values. * p < 0.05 vs. control for the same time point. 
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Figure 10: Effect of OK 236 triterpenoid derivative on cell proliferation of one normal human fibroblast 
cell line (BJ) and two human breast cancer cell lines (Hs 578 T and MCF-7). Cells were seeded (see 
Materials and Methods section for further details) and incubated with OK 236 24 hours later, at various 
concentrations during 24, 48 and 96 hours. Cell proliferation assay was accessed at each time by the 
SRB colorimetric assay. Data are means ± SEM of five independent experiments and are expressed as 
% control values. * p < 0.05 vs. control for the same time point. 
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Figure 11: Effect of OK 221 triterpenoid derivative in cell proliferation of one normal human fibroblast cell 
line (BJ) and two human breast cancer cell lines (Hs 578 T and MCF-7). Cells were seeded (see 
Materials and Methods section for further details) and incubated with OK 221 24 hours later, at various 
concentrations during 24, 48 and 96 hours. Cell proliferation assay was accessed at each time by the 
SRB colorimetric assay. Data are means ± SEM of five independent experiments and are expressed as 
% control values. * p < 0.05 vs. control for the same time point. 
 
3.2 Degree of Mitochondrial Depolarization Caused by DMAP 
Triterpenoid Derivatives on Breast Cancer Lines and BJ 
Fibroblasts 
In order to better understand the results of the SRB assay and to investigate if DMAP 
triterpenoid derivatives present mitochondrial toxic effects (observed as mitochondrial 
depolarization) and cause apoptotic nuclear alterations, a single concentration that 
does not seem to cause a large extension of cell growth inhibition at 48 and 96 hours 
was chosen to treat cell lines. Thirty minutes prior to the end of incubation period, 
cells were incubated with Mitotracker Red (7.3 nM) that is incorporated by 
mitochondria in live cells dependent upon their mitochondrial membrane potential. 
Cells were also labeled with the nuclear fluorescent dye DAPI. The results show that 
OK 236 triterpenoid derivative (Figure 12 to 17) did not have any visible effect on 
mitochondria polarization or nuclear morphology in any of the cell lines in study for 
the concentration (2 µg/ml) and time exposure chosen. In turn, OK 208 (2 µg/ml), DK 
43 (1 µg/ml) and OK 221 (0.125 µg/ml) has a strong effect on mitochondrial 
depolarization for these concentrations in normal BJ fibroblasts (Figure 12 and 13) 
and in both cancer cell lines (Figure 14 to 17) after 48 and 96 hours  of incubation. 
For the MCF-7 cell line, some apoptotic-like nuclei can be observed after 96 hours of 
time exposure in OK 208 and DK 43 -treated groups (Figure 17). Interestingly, OK 
198 (0.5 µg/ml) induces a mild mitochondrial fragmentation in BJ fibrobaslts for this 
concentration and exposure times (Figure 12 and 13) although mitochondria still 
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remains polarized. For both neoplasic cell lines for 48h (Figure 14 and 16) and for 
96h (Figure 15 and 17) mitochondria suffer profound fragmentation and 
depolarization. 
 
 
3.3 DMAP Triterpenoid Derivatives Effects on Isolated 
Hepatic Mitochondria: Evaluation of the Mitochondrial 
Oxygen Consumption 
To test whether DMAP triterpenoid derivatives interfere with mitochondrial respiratory 
parameters, both glutamate/malate (substrate for complex I) and succinate (substrate 
for complex II) were used for mitochondrial energization in the absence and presence 
of increasing concentrations (3 and 6 µg/mg of protein) of the compounds (Figure 23). 
A typical recording of the effect of each one of the tested compounds on 
mitochondrial oxygen consumption is represented in figures 18 to 22. The triterpenoid 
derivative OK 198 seems to exert direct effects in ATP synthase Fo subunit (for 
selected concentrations) since the increase observed in state 2 and state 4 was not 
visible when this specific subunit was inhibited (state oligomycin). More, this effect 
appears to be ATP-dependent because state 4 is further increased when compared 
to state 2. The increase in ADP/O ratio and the tendency to an increase in 
mitochondrial depolarization can further confirm this previous result (Table 1). OK 
208, DK 43 and OK 236 triterpenoid derivatives did not interfere with any 
mitochondrial respiration parameters for selected concentrations except for the RCR 
ratio parameter that was decreased in the presence of the higher concentration of OK 
208 and OK 236. The most powerful compound in cell proliferation (SRB) assays, OK 
221, has also proved to be the most powerful in mitochondrial respiration studies. In 
fact, OK 221 acts in respiratory chain in both glutamate-malate and succinate-
energized mitochondria since maximal respiration are decreased in the presence of 
FCCP (Figure 23). OK 221 also increases passive flux of protons through 
mitochondrial inner membrane as shown by the mitochondrial respiration increase 
when ATP synthase Fo subunit is blocked by oligomycin (state oligomycin). State 2, 
state 3 and state 4 respiratory parameters confirm the same trend of results. The 
value for the RCR ratio of the control group denotes a good mitochondrial 
preparation, which is further confirmed by de ADP/O ratio values. 
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Figure 12: Epifluorescence micrographs showing the effect of DMAP triterpenoid derivatives on nuclear 
morphology and mitochondrial polarization in BJ cell line after 48 hours of time exposure. Cells were 
seeded (see Materials and Methods) and incubated 24 hours later at various concentrations (OK 221: 
0.125 µg/ml; OK 198: 0.5 µg/ml; DK 43: 1 µg/ml; OK 208 and OK 236: 2 µg/ml). Thirty minutes before 
the end of incubation period (48 h) cells were incubated with Mitotracker Red (7.3 nM). Cells were also 
labeled with nuclear fluorescent dye (DAPI) prior microscope visualization. Images of DAPI and 
Mitotracker labeling (left and central panel, respectively) were obtained with a Zeiss Axioskop 2 Plus 
microscope. The right panel corresponds to an overlapping of DAPI and Mitotracker staining. The white 
arrows indicate apoptotic-like nuclei and the green bar represents 20µm.  These results are 
representative of two independent experiments.  
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Figure 13: Epifluorescence micrographs showing the effect of DMAP triterpenoid derivatives on nuclear 
morphology and mitochondrial polarization in BJ cell line after 96 hours of time exposure. Cells were 
seeded (see Materials and Methods) and incubated 24 hours later at various concentrations (OK 221: 
0.125 µg/ml; OK 198: 0.5 µg/ml; DK 43: 1 µg/ml; OK 208 and OK 236: 2 µg/ml). Thirty minutes before 
the end of incubation period (96 h) cells were incubated with Mitotracker (7.3 nM). Cells were also 
labeled with nuclear fluorescent dye (DAPI) prior microscope visualization. Images of DAPI and 
Mitotracker labeling (left and central panel, respectively) were obtained with a Zeiss Axioskop 2 Plus 
microscope. The right panel corresponds to an overlapping of DAPI and Mitotracker staining. The green 
bar represents 20µm. These results are representative of two independent experiments.  
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Figure 14: Epifluorescence micrographs showing the effect of DMAP triterpenoid derivatives on nuclear 
morphology and mitochondrial polarization in Hs 578T cell line after 48 hours of time exposure. Cells 
were seeded (see Materials and Methods) and incubated 24 hours later at various concentrations (OK 
221: 0.125 µg/ml; OK 198: 0.5 µg/ml; DK 43: 1 µg/ml; OK 208 and OK 236: 2 µg/ml). Thirty minutes 
before the end of incubation period (48 h) cells were incubated with Mitotracker Red (7.3 nM). Cells were 
also labeled with nuclear fluorescent dye (DAPI) prior microscope visualization. Images of DAPI and 
Mitotracker labeling (left and central panel, respectively) were obtained with a Zeiss Axioskop 2 Plus 
microscope. The right panel corresponds to an overlapping of DAPI and Mitotracker staining. The green 
bar represents 20µm. These results are representative of two independent experiments.  
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Figure 15: Epifluorescence micrographs showing the effect of DMAP triterpenoid derivatives on nuclear 
morphology and mitochondrial polarization in Hs 578T cell line after 96 hours of time exposure. Cells 
were seeded (see Materials and Methods) and incubated 24 hours later at various concentrations (OK 
221: 0.125 µg/ml; OK 198: 0.5 µg/ml; DK 43: 1 µg/ml; OK 208 and OK 236: 2 µg/ml). Thirty minutes 
before the end of incubation period (96 h) cells were incubated with Mitotracker Red (7.3 nM). Cells were 
also labeled with nuclear fluorescent dye (DAPI) prior microscope visualization. Images of DAPI and 
Mitotracker labeling (left and central panel, respectively) were obtained with a Zeiss Axioskop 2 Plus 
microscope. The right panel corresponds to an overlapping of DAPI and Mitotracker staining. The green 
bar represents 20µm. These results are representative of two independent experiments.  
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Figure 16: Epifluorescence micrographs showing the effect of DMAP triterpenoid derivatives on nuclear 
morphology and mitochondrial polarization in MCF-7 cell line after 48 hours of time exposure. Cells were 
seeded (see Materials and Methods) and incubated 24 hours later at various concentrations (OK 221: 
0.125 µg/ml; OK 198: 0.5 µg/ml; DK 43: 1 µg/ml; OK 208 and OK 236: 2 µg/ml). Thirty minutes before 
the end of incubation period (48 h) cells were incubated with Mitotracker Red (7.3 nM). Cells were also 
labeled with nuclear fluorescent dye (DAPI) prior microscope visualization. Images of DAPI and 
Mitotracker labeling (left and central panel, respectively) were obtained with a Zeiss Axioskop 2 Plus 
microscope. The right panel corresponds to an overlapping of DAPI and Mitotracker staining. The green 
bar represents 20µm. These results are representative of two independent experiments.  
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Figure 17: Epifluorescence micrographs showing the effect of DMAP triterpenoid derivatives on nuclear 
morphology and mitochondrial polarization in MCF-7 cell line after 96 hours of time exposure. Cells were 
seeded (see Materials and Methods) and incubated 24 hours later at various concentrations (OK 221: 
0.125 µg/ml; OK 198: 0.5 µg/ml; DK 43: 1 µg/ml; OK 208 and OK 236: 2 µg/ml). Thirty minutes before 
the end of incubation period (96 h) cells were incubated with Mitotracker (7.3 nM). Cells were also 
labeled with nuclear fluorescent dye (DAPI) prior microscope visualization. Images of DAPI and 
Mitotracker labeling (left and central panel, respectively) were obtained with a Zeiss Axioskop 2 Plus 
microscope. The right panel corresponds to an overlapping of DAPI and Mitotracker staining. The white 
arrows indicate apoptotic-like nuclei and the green bar represents 20µm. These results are 
representative of two independent experiments. 
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Figure 18: Typical recording of the effect of OK 198 triterpenoid derivative on mitochondrial oxygen 
consumption. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard respiratory medium as 
described in Materials and Methods. Respiration was started by adding 10 mM glutamate plus 5 mM 
malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). State 3 was initiated with 187.5 nmol 
of ADP. Oligomycin (1 µg) and FCCP (1 µM) were also added to the system in order to inhibit passive 
flux through the ATP synthase and to uncouple respiration, respectively. Line 1 corresponds to the 
control situation. OK 198 3 µg/mg protein (line 2) and 6 µg/mg protein (line 3) were preincubated with 1 
mg of protein for 1 minute before the respiratory substrate. 
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Figure 19: Typical recording of the effect of OK 208 triterpenoid derivative on mitochondrial oxygen 
consumption. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard respiratory medium as 
described in Materials and Methods. Respiration was started by adding 10 mM glutamate plus 5 mM 
malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). State 3 was initiated with 187.5 nmol 
of ADP. Oligomycin (1 µg) and FCCP (1 µM) were also added to the system in order to inhibit passive 
flux through the ATP synthase and to uncouple respiration, respectively. Line 1 corresponds to the 
control situation. OK 208 3 µg/mg protein (line 2) and 6 µg/mg protein (line 3) were preincubated with 1 
mg of protein for 1 minute before the respiratory substrate. 
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Figure 20: Typical recording of the effect of DK 43 triterpenoid derivative on mitochondrial oxygen 
consumption. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard respiratory medium as 
described in Materials and Methods. Respiration was started by adding 10 mM glutamate plus 5 mM 
malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). State 3 was initiated with 187.5 nmol 
of ADP. Oligomycin (1 µg) and FCCP (1µM) were also added to the system in order to inhibit passive flux 
through the ATP synthase and to uncouple respiration, respectively. Line 1 corresponds to the control 
situation. DK 43 3 µg/mg protein (line 2) and 6 µg/mg protein (line 3) were preincubated with 1 mg of 
protein for 1 minute before the respiratory substrate. 
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Figure 21: Typical recording of the effect of OK 236 triterpenoid derivative on mitochondrial oxygen 
consumption. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard respiratory medium as 
described in Materials and Methods. Respiration was started by adding 10 mM glutamate plus 5 mM 
malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). State 3 was initiated with 187.5 nmol 
of ADP. Oligomycin (1 µg) and FCCP (1 µM) were also added to the system in order to inhibit passive 
flux through the ATP synthase and to uncouple respiration, respectively. Line 1 corresponds to the 
control situation. OK 236 3 µg/mg protein (line 2) and 6 µg/mg protein (line 3) were preincubated with 1 
mg of protein for 1 minute before the respiratory substrate. 
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Figure 22: Typical recording of the effect of OK 221 triterpenoid derivative on mitochondrial oxygen 
consumption. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard respiratory medium as 
described in Materials and Methods. Respiration was started by adding 10 mM glutamate plus 5 mM 
malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). State 3 was initiated with 187.5 nmol 
of ADP. Oligomycin (1 µg) and FCCP (1µM) were also added to the system in order to inhibit passive flux 
through the ATP synthase and to uncouple respiration, respectively. Line 1 corresponds to the control 
situation. OK 221 3 µg/mg protein (line 2) and 6 µg/mg protein (line 3) were preincubated with 1 mg of 
protein for 1 minute before the respiratory substrate. 
 
 
3.4 DMAP Triterpenoid Derivatives Effects on Isolated 
Hepatic Mitochondria: Evaluation of the ∆ψm Fluctuations 
To investigate the effect of triterpenoid derivatives on mitochondrial ∆ψ generation, 
both glutamate/malate (substrate for complex I) and succinate (substrate for complex 
II) were used as substrates. The same range of concentrations used in mitochondrial 
respiratory parameters was used for this assay (3 and 6 µg/mg of protein). A typical 
recording of the effect of each one of the tested compounds on mitochondrial 
transmembrane electric potential are represented in figures 24 to 28. The results for 
maximum ∆ψm, compound-induced depolarization, and phosphorylative lag phase are 
described in tables 1 to 5. The generation of mitochondrial transmembrane electric 
potential shows a slight increase (for increasing concentrations) when compared to 
the control for OK 198 triterpenoid derivative due to its interference with ATP 
synthase Fo subunit (Table 1). For the remaining compounds, there appears to be a 
trend for a depolarization decrease and lag phase increase for increasing 
concentrations of the tested compounds for both glutamate/malate or succinate 
A B 
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energized mitochondria. The increase of the lag phase can be partly explained by the 
induced depolarization of the compound itself due to its positive charge nature. 
However, the depolarization induced by OK 221 is also notoriously linked to direct 
effects on the respiratory chain and to the enhanced permeabilization to protons 
(Figure 23).   
 
 
3.5 DMAP Triterpenoid Derivatives Stimulate the MPT on 
Isolated Hepatic Mitochondria 
The irreversible form of MPT pore opening is accompanied by an increase in 
mitochondrial internal volume (mitochondrial swelling) and by a decrease in 
mitochondrial transmembrane electric potential. The two phenomena can be followed 
experimentally by measuring the changes in the suspension absorbance at 540 nm 
and using a TTP+ selective electrode, respectively. The MPT pore opening was 
induced by Ca2+ in a phosphate-buffer medium and measured in the presence and 
absence of increasing concentrations of DMAP triterpenoid derivatives. Figure 30 
shows a typical recording of the effect of the tested compounds on calcium-induced 
MPT pore opening followed by measuring ∆ψm fluctuations. Increasing concentrations 
of DK 43 and OK 236 have cause calcium-induced Δψm dissipation, with OK 198, 
OK 208 and OK 221 having the more pronounced effect. An additional control with 
FCCP was performed in order to investigate if the MPT pore induction was due to a 
small decrease in ∆ψm, which did not happen. Similarly to what happened in ∆ψm 
fluctuations, mitochondrial swelling was most drastically observed for increasing 
concentrations of OK 198, OK 208 and OK 221, with DK 43 and OK 236 having the 
lower effects for the chosen concentrations (figure 29, Panel A and B). Both 
approaches denote that the effect of tested compounds in MPT pore induction is 
dose-dependent. The permeability transition pore inhibitor [72], cyclosporin A, was 
able to prevent both mitochondrial swelling and ∆ψm dissipation, confirming that this 
effect is caused by MPT pore induction. 
 
 
 
 36 Dimethylaminopyridine derivatives of lupane triterpenoids acting as mitochondrial-directed agents on breast cancer cells 
 
Glutamate/ Malate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
200
250
Control
3 µg/mg protein
6 µg/mg protein
*
S
ta
te
 2
 (
%
 t
o
 c
o
n
tr
o
l)
 
Succinate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
200
* Control
3 µg/mg protein
6 µg/mg protein*
*
S
ta
te
 2
 (
%
 t
o
 c
o
n
tr
o
l)
 
Glutamate/ Malate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
Control
3 µg/mg protein
6 µg/mg protein
*
S
ta
te
 3
(%
 t
o
 c
o
n
tr
o
l)
 
Succinate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
Control
3 µg/mg protein
6 µg/mg protein
*
*
*
S
ta
te
 3
 (
%
 t
o
 c
o
n
tr
o
l)
 
Glutamate/ Malate
OK 198 OK 208 DK 43 OK 236 OK 221
0
100
200
300
400
Control
3 µg/mg protein
6 µg/mg protein
*
S
ta
te
 4
 (
%
to
 c
o
n
tr
o
l)
 
Succinate
OK 198 OK 208 DK 43 OK 236 OK 221
0
100
200
300
*
* *
Control
3 µg/mg protein
6 µg/mg protein*
S
ta
te
 4
 (
%
to
 c
o
n
tr
o
l)
 
Glutamate/ Malate
OK 198 OK 208 DK 43 OK 236 OK 221
0
100
200
300
400
Control
3 µg/mg protein
6 µg/mg protein
*
S
ta
te
 O
li
g
o
m
y
c
in
 (
%
 t
o
 c
o
n
tr
o
l)
 
Succinate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
200
250
Control
3 µg/mg protein
6 µg/mg protein
*
*
S
ta
te
 O
li
g
o
m
y
c
in
 (
%
 t
o
 c
o
n
tr
o
l)
 
 
 
 
 
Results 37 
 
Glutamate/ Malate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
Control
3 µg/mg protein
6 µg/mg protein
*
*
S
ta
te
 F
C
C
P
(%
 t
o
 c
o
n
tr
o
l)
 
Succinate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
Control
3 µg/mg protein
6 µg/mg protein
*
*
S
ta
te
 F
C
C
P
(%
 t
o
 c
o
n
tr
o
l)
 
Glutamate/ Malate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
Control
3 µg/mg protein
6 µg/mg protein
*
*
*
*R
C
R
(%
 t
o
 c
o
n
tr
o
l)
 
Succinate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
200
Control
3 µg/mg protein
6 µg/mg protein
*
***
*
*
*
R
C
R
(%
 t
o
 c
o
n
tr
o
l)
 
Glutamate/ Malate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
Control
3 µg/mg protein
6 µg/mg protein
*
*
A
D
P
/O
(%
 t
o
 c
o
n
tr
o
l)
 
Succinate
OK 198 OK 208 DK 43 OK 236 OK 221
0
50
100
150
Control
3 µg/mg protein
6 µg/mg protein
*
*
A
D
P
/O
(%
 t
o
 c
o
n
tr
o
l)
 
 
 
 
 
 
Figure 23: Effects of triterpenoid derivatives on mitochondrial respiraty parameters energized with 10 mM 
glutamate/ 5 mM malate (left panel) or 5 mM succinate (right panel). Mitochondria were incubated in 1ml 
respiration medium (see Materials and Methods section). ADP (187.5 nmol) was added to induce state 3 
respiration. Oligomycin (1 µg) and FCCP (1 µM) were added to the system in order to inhibit passive flux 
through ATP synthase and to uncouple respiration, respectively. The RCR was calculated as the ratio 
between sate 3 and sate 4 respiration. The ADP/O ratio was calculated as the number of nmol ADP 
phosphorylated by natoms of O consumed during ADP phosphorylation.  Data were expressed as % to 
control and are means ± SEM of tree different preparations. * p < 0.05 vs. control. Control values for Complex I: 
State 2 = 19.0 ± 4.1 natoms O/min / mg protein; State 3 = 124.1 ± 20.2 natoms O/min / mg protein; State 4 = 18.0 ± 5.2 natoms O/min / 
mg protein; State Oligomycin = 9.3 ± 2.9 natoms O/min / mg protein; ADP/O = 2.9 ± 0.1; RCR = 9.3 ± 2.0 (Mean ± SEM, n=3). Control 
values for Complex II: State 2 = 22.3 ± 5.5 natoms O/min / mg protein; State 3 = 131.8 ± 8.5 natoms O/min / mg protein; State 4 = 18.3 
± 3.3 natoms O/min / mg protein; State Oligomycin= 8.3 ± 2.5; natoms O/min / mg protein; State FCCP = 158.2 ± 25.2; ADP/O = 2.0 ± 
0.2; RCR = 6.6 ± 2.1(Means ± SEM, n=3). 
              Control  
             3 µg/mg protein 
             6 µg/mg protein 
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Figure 24: Representative recording of the effect of OK 198 triterpenoid derivative on mitochondrial 
transmembrane electric potential. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard 
reaction medium as described in Materials and Methods. Mitochondria were energized by adding 5 mM 
glutamate/2.5 mM malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). ADP (125 nmol) 
was added to initiate state 3 and valinomycin (Val.) 0.2 µg was added to the system in order to confirm if 
OK 198 interferes with the TPP
+
 electrode. OK 198 3 µg/mg protein and 6 µg/mg protein were 
preincubated with 1 mg of protein for 1 minute prior the ADP addition. 
 
Table 1:  Effect of OK 198 on glutamate-malate (for complex I) and succinate (substrate for complex II) 
energized mitochondria. ∆ψm Max., compound depolarization, ADP depolarization and lag phase were 
measured indirectly, using a TTP
+ 
selective electrode (see Materials and Methods section). Data are 
means ±SEM of tree independent preparations. * p < 0.05 vs. control. Parenthesis values represent % to 
control. n.m. = not measurable. 
 
∆ψm max. 
(-mV) 
Compound 
depolarization 
(-mV) 
ADP 
depolarization 
(-mV) 
Lag phase 
(sec) 
Complex I     
Control 
223.8 ± 7.5 
(100%) 
n.m. 
20.2 ± 5.5 
(100%) 
32.8 ± 8.8 
(100%) 
3 μg/mg 
224.8 ± 7.0 
(100.4% ± 0.3) 
4.6 ± 0.7 
 
22.5 ± 4.9 
(112.3% ± 7.8) 
28.8 ± 3.8 
(90.0% ± 13.5) 
6 μg/mg 
224.6 ± 7.3 
(100.3% ± 0.2) 
5.7 ± 1.4 
 
22.6 ± 4.9 
(112.9% ± 7.4) 
31.0 ± 8.5 
(94.4% ± 5.6) 
Complex II     
Control 
225.4 ± 4.1 
(100%) 
n.m. 
26.7 ± 5.5 
(100%) 
37.0 ± 3.6 
(100%) 
3 μg/mg 
225.6 ± 4.6 
(100.1% ± 0.9) 
3.0 ± 1.3 
 
28.5 ± 6.9 
(106.1% ± 10.4) 
39.0 ± 5.2 
(105.2% ± 5.3) 
6 μg/mg 
224.4 ± 5.8 
(99.6% ± 1.2) 
3.5 ± 1.1 
 
27.8 ± 6.6 
(104.2% ± 16.0) 
42.0 ± 6.0 
(113.2% ± 5.9) 
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Figure 25: Representative recording of the effect of OK 208 triterpenoid derivative on mitochondrial 
transmembrane electric potential. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard 
reaction medium as described in Materials and Methods. Mitochondria were energized by adding 5 mM 
glutamate/2.5 mM malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). ADP (125 nmol) 
was added to initiate state 3 and valinomycin (Val.) 0.2 µg was added to the system in order to confirm if 
OK 208 interferes with the TPP
+
 electrode. OK 208 3 µg/mg protein and 6 µg/mg protein were 
preincubated with 1 mg of protein for 1 minute prior the ADP addition. 
 
Table 2: Effect of OK 208 on glutamate-malate (for complex I) and succinate (substrate for complex II) 
energized mitochondria. ∆ψm Max., compound depolarization, ADP depolarization and lag phase were 
measured indirectly, using a TTP
+ 
selective electrode (see Materials and Methods section). Data are 
means ±SEM of tree independent preparations. * p < 0.05 vs. control. Parenthesis values represent % to 
control. n.m. = not measurable. 
 
∆ψm max. 
(-mV) 
Compound 
depolarization 
(-mV) 
ADP 
depolarization 
(-mV) 
Lag phase 
(sec) 
Complex I     
Control 
223.8 ± 7.5 
(100%) 
n.m. 
20.2 ± 5.5 
(100%) 
35.8 ± 10.3 
(100%) 
3 μg/mg 
224.8 ± 8.0 
(100.4% ± 0.8) 
10.9 ± 2.6 
 
18.5 ± 3.4 
(94.2% ± 17.9) 
42.8 ± 7.4 
(121.6% ± 14.1) 
6 μg/mg 
225.8 ± 5.4 
(100.9% ± 1.1) 
16.3 ± 3.7 
 
14.6 ± 3.1 
(73.9% ± 13.8) 
46.5 ± 19.1 
(127.7% ± 16.8) 
Complex II     
Control 
230.9 ± 12.2 
(100%) 
n.m. 
33.6 ± 7.9 
(100%) 
31.0 ± 5.7 
(100%) 
3 μg/mg 
231.8 ± 11.7 
(100.4% ± 0.3) 
10.5 ± 2.7 
 
30.3 ± 7.0 
(90.2% ± 3.3) 
36.0 ± 7.6 
(116.8% ± 2.9) 
6 μg/mg 
228.3 ± 8.7 
(99.0% ± 1.6) 
15.4 ± 3.5 
 
27.8 ± 7.2 
(82.7% ± 7.0) * 
45.5 ± 3.5 
(148.2% ± 15.6) * 
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Figure 26: Representative recording of the effect of DK 43 triterpenoid derivative on mitochondrial 
transmembrane electric potential. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard 
reaction medium as described in Materials and Methods. Mitochondria were energized by adding 5 mM 
glutamate/2.5 mM malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). ADP (125 nmol) 
was added to initiate state 3 and valinomycin (Val.) 0.2 µg was added to the system in order to confirm if 
DK 43 interferes with the TPP
+
 electrode. DK 43 3 µg/mg protein and 6 µg/mg protein were preincubated 
with 1 mg of protein for 1 minute prior the ADP addition. 
 
Table 3: Effect of DK 43 on glutamate-malate (for complex I) and succinate (for complex II) energized 
mitochondria. ∆ψm Max., compound depolarization, ADP depolarization and lag phase were measured 
indirectly, using a TTP
+ 
selective electrode (see Materials and Methods section). Data are means ±SEM 
of tree independent preparations. * p < 0.05 vs. control. Parenthesis values represent % to control. n.m. 
= not measurable. 
 
∆ψm max. 
(-mV) 
Compound 
depolarization 
(-mV) 
ADP 
depolarization 
(-mV) 
Lag phase 
(sec) 
Complex I     
Control 
221.4 ± 3.9 
(100%) 
n.m. 
23.0 ± 1.9 
(100%) 
27.8 ± 1.1 
(100%) 
3 μg/mg 
222.0 ± 1.2 
(100.3% ± 1.3) 
7.3 ± 1.3 
 
26.5 ± 2.1 
(115.0% ± 5.1) 
27.8 ± 3.2 
(100.3% ± 15.3) 
6 μg/mg 
221.6 ± 1.7 
(100.1% ± 1.7) 
15.7 ± 3.6 
 
23.5 ± 3.2 
(102.8% ± 19.6) 
45.0 ± 8.5 
(162.9% ± 36.8) 
Complex II     
Control 
230.9 ± 12.2 
(100%) 
n.m. 
33.6 ± 7.9 
(100%) 
33.3 ± 6.5 
(100%) 
3 μg/mg 
232.3 ± 13.0 
(100.6% ± 0.3) 
10.6 ± 6.4 
 
36.2 ± 3.2 
(110.7% ± 18.8) 
38.0 ± 1.7 
(116.3% ± 18.0) 
6 μg/mg 
227.8 ± 14.0 
(98.7% ± 2.1) 
16.6 ± 9.2 
 
29.9 ± 4.4 
(92.8% ± 29.7) 
53.0 ± 7.5 * 
(164.8% ± 46.2) * 
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Figure 27: Representative recording of the effect of OK 236 triterpenoid derivative on mitochondrial 
transmembrane electric potential. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard 
reaction medium as described in Materials and Methods. Mitochondria were energized by adding 5 mM 
glutamate/2.5 mM malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). ADP (125 nmol) 
was added to initiate state 3 and valinomycin (Val.) 0.2 µg was added to the system in order to confirm if 
OK 236 interferes with the TPP
+
 electrode. OK 236 3 µg/mg protein and 6 µg/mg protein were 
preincubated with 1 mg of protein for 1 minute prior the ADP addition. 
 
Table 4: Effect of OK 236 on glutamate-malate (for complex I) and succinate (for complex II) energized 
mitochondria. ∆ψm Max., compound depolarization, ADP depolarization and lag phase were measured 
indirectly, using a TTP
+ 
selective electrode (see Materials and Methods section). Data are means ±SEM 
of tree independent preparations. The results were not statistically different (treatments vs. control) for a 
p value < 0.05. Parenthesis values represent % to control. n.m. = not measurable. 
 
∆ψm max. 
(-mV) 
Compound 
depolarization 
(-mV) 
ADP 
depolarization 
(-mV) 
Lag phase 
(sec) 
Complex I     
Control 
224.8 ± 10.9 
(100%) 
n.m. 
25.3 ± 5.6 
(100%) 
36.5 ± 9.2 
(100%) 
3 μg/mg 
225.3 ± 12.5 
(100.2% ± 0.7) 
6.2 ± 0.1 
 
23.4 ± 2.8 
(93.6% ± 9.3) 
36.8 ± 5.3 
(102.1% ± 11.2) 
6 μg/mg 
225.3 ± 13.3 
(100.2% ± 1.1) 
10.2 ± 3.9 
 
20.3 ± 1.2 
(81.8% ± 13.2) 
46.0 ± 1.4 
(129.7% ± 28.8) 
Complex II     
Control 
232.5 ± 16.8 
(100%) 
n.m. 
36.1 ± 8.2 
(100%) 
36.5 ± 4.9 
(100%) 
3 μg/mg 
231.7 ± 15.7 
(99.7% ± 0.5) 
6.2 ± 0.4 
 
30.6 ± 3.4 
(85.8% ± 9.9) 
38.3 ± 9.5 
(104.0% ± 12.1) 
6 μg/mg 
229.2 ± 14.7 
(98.6% ± 0.8) 
8.3 ± 0.6 
 
27.7 ± 3.9 
(79.9% ± 29.0) 
40.0 ± 4.2 
(109.8% ± 3.3) 
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Figure 28: Representative recording of the effect of OK 221 triterpenoid derivative on mitochondrial 
transmembrane electric potential. Hepatic mitochondria (1 mg) were incubated in 1 ml of standard 
reaction medium as described in Materials and Methods. Mitochondria were energized by adding 5 mM 
glutamate/2.5 mM malate (Panel A) or 5 mM succinate with 3 µM rotenone (Panel B). ADP (125 nmol) 
was added to initiate state 3 and valinomycin (Val.) 0.2 µg was added to the system in order to confirm if 
OK 221 interferes with the TPP
+
 electrode. OK 221 3 µg/mg protein and 6 µg/mg protein were 
preincubated with 1 mg of protein for 1 minute prior the ADP addition. 
 
Table 5: Effect of OK 221 on glutamate-malate (for complex I) and succinate (for complex II) energized 
mitochondria. ∆ψm Max., compound depolarization, ADP depolarization and lag phase were measured 
indirectly, using a TTP
+ 
selective electrode (see Materials and Methods section). Data are means ±SEM 
of tree independent preparations. * p < 0.05 vs. control. Parenthesis values represent % to control. n.m. 
= not measurable. 
 
∆ψm max. 
(-mV) 
Compound 
depolarization 
(-mV) 
ADP 
depolarization 
(-mV) 
Lag phase 
(sec) 
Complex I     
Control 
228.8 ± 5.5 
(100%) 
n.m. 
17.9 ± 6.3 
(100%) 
33.5 ± 4.3 
(100%) 
3 μg/mg 
228.7 ± 7.0 
(100.0% ± 0.7) 
12.0 ± 2.6 
 
19.5 ± 4.0 
(112.1% ± 15.9) 
51.0 ± 7.9 * 
(151.9% ± 5.7) * 
6 μg/mg 
229.2 ± 4.9 
(100.2% ± 0.3) 
22.3 ± 6.9 
 
13.5 ± 1.1 
(79.5% ± 18.1) 
63.3 ± 4.5 * 
(190.3% ± 16.1) * 
Complex II     
Control 
227.9 ± 0.3 
(100%) 
n.m. 
25.1 ± 6.4 
(100%) 
43.0 ± 8.7 
(100%) 
3 μg/mg 
228.1 ± 1.5 
(100.1% ± 0.8) 
13.8 ± 1.6 
 
22.4 ± 6.0 
(88.9% ± 7.0) 
40.3 ± 8.1 
(96.3% ± 25.2) 
6 μg/mg 
227.7 ± 2.7 
(99.9% ± 1.3) 
24.8 ± 5.6 
 
13.8 ± 4.7 
(54.6% ± 11.3) * 
57.0 ± 3.0 
(137.7% ± 38.3) 
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Figure 29: Typical recording of the effect of increasing concentrations of triterpenoid derivatives on 
calcium-induced MPT pore followed by measuring variations in mitochondrial volume and evaluated by 
the decrease of optical density at 540nm (Panel A). Hepatic mitochondria (1 mg) were suspended in 2 ml 
of swelling medium and energized by succinate (5 mM) as described in Material and Methods section. 
Triterpenoid derivatives at various concentrations were allowed to incubate with mitochondria. Calcium 
(depending on the mitochondrial preparation) was added to the system in order to induce MPT pore. For 
each assay, a negative control with cyclosporin A was performed in order to prevent mitochondrial 
swelling. Cs A was preincubated with mitochondrial suspension before the addition of tested compounds 
(at maximum concentrations) and calcium. Panel B represents the triterpenoid derivatives effect on Ca
2+
-
induced mitochondrial swelling evaluated by the decrease of optical density at 540nm.  Data are means 
± SEM of three to four independent preparations. * p < 0.05 vs. control. Values are expressed as % to 
the control. 
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Figure 30: Representative recording of the effect of increasing concentrations of triterpenoid derivatives 
on calcium-induced MPT pore indirectly followed by measuring ∆ψm fluctuations, using a TTP
+ 
selective 
electrode (see Materials and Methods). Mitochondria were incubated in 1 ml of swelling medium and 
energized by succinate (5 mM). Triterpenoid derivatives at various concentrations were incubated for 2 
minutes with mitochondria. Calcium (depending on the mitochondrial preparation) was added to the 
system in order to induce MPT pore. Control with FCCP was performed in order to verify if MPT pore 
was induced due to the decrease of ∆ψm. Control with Cs A was carried out for OK 198 and for other 
compounds (data not shown) in order to prevent mitochondrial swelling. Cs A was preincubated with 
mitochondrial suspension before the addition of tested compounds (highest concentrations) and calcium. 
Calcium additions are represented by grey arrows. 
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Discussion 
 
 
 
 
 
 
 
 
 
The increased resistance to apoptosis induction is a common feature in cancers. 
Since mitochondria occupy a strategic position between bioenergetic/biosynthetic 
metabolism and cell death regulation, these organelles emerged as idealized targets 
for cancer therapy. Thus, compounds that directly affect mitochondrial functions and 
trigger apoptosis are considered as very promising anti-cancer agents. Triterpenoids 
are a class of natural occurring compounds with ubiquitous distribution and whose 
anticancer activity was already documented and observed to be dependent on 
apoptosis induction via direct mitochondrial alterations. Betulinic acid is one of such 
natural compounds that display notable level of discrimination in promoting apoptosis 
in some cancer cell lines such as melanoma [61], glioma and ovarian carcinoma [60]. 
Although extracted from flora in large amounts, the use of these triterpenoids as it 
stands in nature remains quite limited. In this way, taking advantage of quantitative 
structure-activity relationships (QSARs), derivatives of triterpenoids can be 
synthesized in order to produce more active and selective compounds. With this in 
mind, dimethylaminopyridine (DMAP) derivatives of lupane triterpenoids were 
synthesized based on birch bark lupane triterpenoids betulin and betulinic acid, and 
are under consideration for their potent effect on cancer cell lines [60]. 
Our research group has previously tested a number of DMAP derivatives on human 
melanoma cell lines [56]. These compounds induced mitochondrial fragmentation and 
depolarization, along with an inhibition of cell proliferation. The potency of their effects 
was correlated with the number, position, and orientation of the DMAP groups. 
Overall, the extent of proliferation inhibition was shown to mirror the effectiveness of 
mitochondrial disruption.  
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The present work is a logical sequence to the initial results, aiming at understanding 
in more detail the mechanisms behind the mitochondrial toxicity observed in the 
previous study, trying at the same time to correlate those same effects with a possible 
selective anti-cancer activity. The latter was here also tested by performing 
proliferation assays on two human breast cancer cell lines vs. one non-tumor cell line. 
All the DMAP triterpenoid derivatives in study have a hydrophobic central region 
composed by four cyclohexane rings and one cyclopentane ring which corresponds to 
betulinic acid. Polar groups were added to the structure backbone in order to provide 
an amphiphilic character to molecules. This anellar-like structure gives a planar 
geometry to molecules and provides affinity to hydrocarbon-chain of fatty acids of 
phospholipids. These polar groups are protonated at physiological pH which means 
that the compounds are likely to be positively charged in the physiological 
environment and preferentially interact with anionic membrane lipids. Once inserted in 
plasma membrane the orientation and localization of DMAP groups promotes their 
rapid diffusion towards the cytosol. It is expected that once in cytosol they move into 
mitochondria driven by electrophoretic movement.  
Data obtained in the present study demonstrate that OK 198 (Figure 7), OK 208 
(Figure 8) and DK 43 (Figure 9) triterpenoid derivatives inhibit cell proliferation 
especially in cancer cell lines for the concentrations and time points in study. It is a 
very interesting result since that the main goal of anticancer drugs is to kill more 
effectively cancer cells, sparing normal cells [53] although based in this technique we 
cannot conclude if they undergo cell death induction or cell cycle arrest.  
According to the previously study that reported mitochondrial structure and function 
alterations in the presence of these triterpenoid derivatives in melanoma cells [60] 
and in order to better understand the results from the proliferation assay, we further 
used epifluorescence microscopy to investigate in situ mitochondrial effects and 
nuclear apoptotic alterations. The fluorescent probe Mitotracker Red was used not 
only to detect alterations in mitochondrial membrane polarization but also to have an 
idea of the mitochondrial network morphology. OK 236 does not present any visible 
effect on cell growth, mitochondrial morphology or polarization for the cell lines, 
concentrations and time points chosen (Figure 10; Figure 12 to 17). By its turn, OK 
221 proved to be a strong cell proliferation inhibitor for all the cell lines and a potent 
disruptor of mitochondrial function (Figure 11; Figure 12 to 17). Surprisingly, for both 
time points tested (48 and 96h) the selected concentration of OK 198 (0.5 µg/ml) 
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induced a mild mitochondrial fragmentation in normal fibroblasts and a profound 
mitochondrial fragmentation and depolarization for cancer cell lines (Figure 12 to 17). 
Mitochondrial fission can be associated with apoptosis induction [1, 31] and oxidative 
stress [74] which may suggest that OK 198 may cause oxidative stress, which should 
be verified in further studies. Despite the concentrations chosen for OK 208 (2 µg/ml) 
and DK 43 (1 µg/ml) did not present a markedly effect on cell growth inhibition in 
untransformed cell line when compared with cancer cell lines (Figure 8 and 9, 
respectively), the same induced a striking fragmentation and depolarization of the 
mitochondrial network (Figure 12 to 17). Some apoptotic-like nuclei are visible after 
96 hours of time exposure in MCF-7 (Figure 17) which supports the idea that 
triterpenoid derivatives could exert their toxic activity by promoting apoptosis. In 
general, these results are in agreement with the previous study [60].The results for 48 
and 96 hours were not dissimilar probably because only the most resistant adherent 
cells are visible.  
Since the previous study [60] demonstrated that mitochondria structure and function 
is compromised in melanoma cell lines after incubation with the triterpenoid 
derivatives presence, we investigated whether the test compounds exert direct effects 
on isolated rat hepatic mitochondria in order to gain more mechanistical insights. 
Although normal hepatic and cancer cell mitochondria present some structural and 
functional differences [75], we believe that sufficient similarities exist to justify using 
isolated hepatic mitochondria as models to gain insight into the interactions of tested 
compounds with mitochondria.  Isolated mitochondrial fractions have been used as a 
biological model by pharmaceutical companies as a sensitive and reliable biosensor 
for drug-induced toxicity [2]. 
The results show that OK 198 appears to have an effect in ATP synthase Fo subunit 
as suggested by the decrease in ADP/O ratio (Figure 23) and the tendency to 
mitochondrial depolarization increase (Table 1). OK 236, DK 43 e OK 208 did not 
present any alteration in respiratory parameters, with the exception of the RCR 
decrease for OK 236 and DK 43 (Figure 23). The results also suggest that some of 
the compounds studied may present a mix of effects between inhibition of the 
respiratory chain and uncoupling effect, which is observed, for example by the 
immediate depolarization observed upon addition of the compounds to the 
mitochondrial suspension. Further assays will be performed to clarify which is the 
case for each compound. One example of multiple levels of mitochondrial toxicity is 
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OK 221, which appears to have a protonophoretic/ uncoupler effect and at the same 
time appearing to inhibit the phosphorylative system (Figure 23), seen as a tendency 
to decrease the depolarization induced by ADP (Table 5). Both effects contribute to 
the increase in phosphorylative lag phase and a drop in the ADP/O.  
Two distinct experiments (mitochondrial swelling and ∆ψm fluctuations) demonstrate 
that increasing concentrations of OK 198, OK 208 and OK 221 induce the 
mitochondrial permeability transition pore (Figure 29). The results obtained for OK 
198 and OK 208 are very interesting for the present study since both induce the 
mitochondrial permeability transition pore at concentrations that do not present a 
marked toxic effect on mitochondrial metabolism (Figure 23). The maintenance of the 
mitochondrial metabolism integrity is extremely important because apoptosis is an 
ATP-dependent process [4]. With these results, it is predictable that OK 198 and OK 
208 DMAP derivatives may induce cell death through a mitochondrial permeability 
transition pore-related mechanism. It has been previously demonstrated that this 
phenomenon is considered very important, not only in the crossroad between 
apoptosis and necrosis, but also in organ dysfunction during different pathologies 
[76]. As observed in cell experiments and mitochondrial oxygen consumption, OK 236 
did not present any effect in MPTP for the concentrations and time points tested 
(Figure 29), which is again convincing evidence that mitochondrial effects underlie the 
toxicity of these agents. Unlike what was expected from results in cells, DK 43 did not 
shown toxicity on any mitochondrial respiratory parameter studied (Figure 23) or 
caused induction of the mitochondrial permeability transition pore (Figure 29) for the 
concentrations tested which leads us the idea that DK 43 may exert its activity on 
cancer cells independently of direct mitochondrial effects. 
We can also speculate that DMAP triterpenoid derivatives activity depends on DMAP 
group position. Although OK 198 and DK 43 are theoretically similar (Figure 6) since 
both compounds have the same number of positive charges at physiological pH and 
differ only in the DMAP position groups, their effect are notably distinct. As expected 
for OK 236, the lower affinity to lipid membrane and low positive net charge was 
reflected by the absence of activity in models tested which confirm that compounds 
must have an amphiphilic character and be positively charged to exert their biological 
activity on organelles with the highest negative potential inside, such as mitochondria. 
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In general, the present work corroborate the idea that DMAP triterpenoid derivatives 
are promising in cancer therapy since that some of the compounds present somewhat 
more selectivity towards cancer cells than normal cells. Moreover, mitochondrial 
experiments demonstrate that these agents can directly induce MPT pore in a 
concentration that did not interfere with normal mitochondrial metabolism, suggesting 
this may be a very valid mechanism that explains their toxicity. Further assays are 
clearly needed to explore the mechanisms of mitochondrial toxicity of the test 
compounds in more detail, since the borderline between a desired pharmacological 
effect (i.e. disruption of mitochondrial function in cancer cells) and a toxic side-effect 
(mitochondrial toxicity in non-target organs) is very thin indeed. 
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